SOPHiA GENETICS (SOPH) Q2 2026 earnings review
Accelerating Revenue and Narrowing Losses Validate AI Platform
SOPHiA GENETICS delivered a breakout quarter, with revenue growth accelerating to 27% YoY ($23.3M) and Net Dollar Retention expanding to an impressive 117%. The 'land and expand' strategy is working, driven by a 60% volume surge in the U.S. and an 80% revenue jump in Liquid Biopsy applications. Importantly, the company is demonstrating operating leverage: Adjusted EBITDA loss narrowed by 27% YoY to $8.8M. Armed with $57.5M in fresh capital from a recent public offering, management raised full-year revenue guidance and reaffirmed its target of reaching adjusted EBITDA breakeven by late 2026.
🐂 Bull Case
U.S. revenue grew 64% YoY, driven by a 60% surge in analysis volume. Key customer go-lives (Geisinger, NYU Langone) prove the platform's value to top-tier decentralized healthcare networks.
Adjusted EBITDA loss shrank to $8.8M. With $107.7M in cash after a successful Q2 public offering, the company has sufficient runway to achieve its projected breakeven by the end of 2026 without further dilution.
🐻 Bear Case
Reported gross margin dipped to 65% from 67% a year ago. Cost of revenue grew 36% YoY, heavily outpacing the 27% revenue growth due to a mix shift toward lower-margin BioPharma and services.
The Guardant Health patent litigation remains a costly overhang, adding $1.1M in net legal expenses in Q2 alone and inflating G&A costs by 24% YoY.
⚖️ Verdict: 🟢
Bullish. The 27% revenue growth paired with 27% narrowing in Adjusted EBITDA loss proves the underlying unit economics of the SaaS model. If U.S. adoption continues at this pace, breakeven in 2026 is highly achievable.
Key Themes
U.S. Decentralization Trend is a Major Tailwind
The U.S. market is fully embracing decentralized genomics testing. North America (NORAM) revenue surged 61% YoY to $5.1M in Q2, with the U.S. specifically growing 64%. New strategic deployments at NYU Langone and Geisinger Health highlight SOPHiA's ability to capture high-value enterprise accounts moving testing in-house.
Liquid Biopsy Driving Higher ASPs
The MSK-ACCESS liquid biopsy application is a primary growth engine. Revenue for this application grew 80% YoY in Q2. With 80 total customers signed across 30 countries and over half still yet to complete implementation, this high-value test provides immense visible revenue backlog.
BioPharma Shifts from Headwind to Growth Driver
The BioPharma segment, previously a drag, is accelerating. The company signed a milestone agreement with AstraZeneca to launch two Companion Diagnostic (CDx) programs. This is the first CDx agreement in company history, closing the loop between pharma trials and clinical rollout on the SOPHiA network.
Gross Margin Compression from Mix Shift
While the BioPharma resurgence is positive for top-line growth, it contradicts the high-margin SaaS narrative. Cost of revenue jumped 36% YoY to $8.2M, pushing reported gross margins down to 65% from 67%. Management explicitly stated this decrease is 'largely the result of growth in BioPharma customers and services, both of which typically carry lower gross margins than clinical genomics.'
Guardant Health Litigation Costs
Patent infringement lawsuits from Guardant Health remain a drain on resources. Net legal expenses tied to the litigation cost the company $1.1M in Q2, driving a 24% YoY surge in General & Administrative costs. While SOPHiA won some early European rulings and recouped interim costs, the U.K. trial is still pending.
Memorial Sloan Kettering AI Joint Venture
SOPHiA signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering (MSK) to create an 'AI Lab of the Future' joint venture. This moves the relationship from a simple licensing deal (MSK-IMPACT/ACCESS) to co-developing next-generation multimodal clinical intelligence tools.
Other KPIs
Accelerating. Up significantly from 107% in Q2 2025. This proves the company's 'land and expand' strategy is highly effective, as existing customers dramatically increased analysis volumes and adopted higher-priced applications like MSK-ACCESS.
Accelerating. Volume grew 22% YoY, up from 94,562 in the prior year. The growth is fueled primarily by the HemOnc and Hereditary Cancer portfolios, validating the stickiness of the core clinical business.
Stable. Up from 490 a year ago. The company added 24 new core genomic customers in Q2 2026. The focus is shifting successfully from pure logo acquisition to extracting higher value per logo.
Guidance
Accelerating. Management raised the lower and upper bounds from the previous $92 - $94 million range. The new midpoint ($95M) implies ~23% YoY growth, marking a clear acceleration from 19% growth achieved in FY25.
Stable. The company maintained its guidance range, which implies a significant ~27% improvement from the $41.5 million loss recorded in FY25. Management reiterated their expectation to approach breakeven by the end of 2026.
Key Questions
BioPharma Margin Profile
BioPharma growth compressed gross margins this quarter. As the AstraZeneca CDx programs scale, what is the long-term margin profile of this segment compared to the core clinical business?
Implementation Backlog Velocity
With 80 customers signed for MSK-ACCESS and more than half yet to implement, what are the current bottlenecks in go-live timelines, and how is AI being used to speed up onboarding?
Guardant Litigation Exposure
Despite early wins in the EU, the U.K. litigation is moving forward. What is the worst-case financial exposure or potential market block in the U.K., and when do you expect final resolution?
MSK Joint Venture Capital Needs
The MOU for the Memorial Sloan Kettering Joint Venture is an exciting development. Will this require significant upfront capital investment from SOPHiA, and how will ownership be structured?